ID   SF295/hCPT50
AC   CVCL_WV58
DR   cancercelllines; CVCL_WV58
DR   Wikidata; Q98132451
RX   PubMed=17984197;
CC   Population: Caucasian.
CC   Doubling time: 69 hours (PubMed=17984197).
CC   Selected for resistance to: ChEBI; CHEBI:144047; Homocamptothecin.
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg233Ter (c.697C>T); ClinVar=VCV000007813; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Brain, left temporal lobe; UBERON=UBERON_0002808.
DI   NCIt; C3058; Glioblastoma
DI   ORDO; Orphanet_360; Glioblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1690 ! SF295
SX   Female
AG   67Y
CA   Cancer cell line
DT   Created: 05-07-19; Last updated: 05-10-23; Version: 9
//
RX   PubMed=17984197; DOI=10.1124/mol.107.041178;
RA   Liao Z.-Y., Robey R.W., Guirouilh-Barbat J., To K.K.-W., Polgar O.,
RA   Bates S.E., Pommier Y.;
RT   "Reduced expression of DNA topoisomerase I in SF295 human glioblastoma
RT   cells selected for resistance to homocamptothecin and diflomotecan.";
RL   Mol. Pharmacol. 73:490-497(2008).
//